Development

Excipients for High-Concentration Biologics

Careful selection is essential for achieving viscosity reduction without protein destabilization.

The Rise of Regenerative Medicines

Regenerative medicines boast a rich clinical pipeline.

What’s Next for COVID-19 Vaccines and Variants?

New technologies and treatments are emerging—along with new variants.

Johnson & Johnson Launches Next Satellite Center for Global Health Discovery

April 26, 2022

Johnson & Johnson has launched its next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town.

EIB Provides €15 million to IRBM

April 21, 2022

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.

Otsuka Pharmaceutical and Osaka University Enter Exclusive License Agreement

April 20, 2022

Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.

AmoyDX and AstraZeneca Enter Master Collaboration Agreement

April 18, 2022

AmoyDX has entered a Master Collaboration Agreement with AstraZeneca for multiple companion diagnostics programs in China, EU, and Japan.

ReiThera and Exothera Collaborate on Manufacturing Vaccines for Low and Middle-income Countries

April 14, 2022

ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.

Examining Phage Therapy

April 13, 2022

Battles against antibiotic-resistant bacteria can be won with bacteriophages.

Developing Excipients for High-Concentration Biologic Formulations

April 13, 2022

With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.

Opus Enters Collaboration with Resilience for AAV-Based Gene Therapy Development and Manufacturing

April 12, 2022

Opus enters a strategic collaboration with Resilience for AAV-based gene therapy development and manufacturing for inherited retinal diseases.

IAVI and Moderna Partner to Tackle Global Health Priorities Using mRNA for Vaccines and Antibodies

April 11, 2022

IAVI and Moderna have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health issues.

Evonetix Receives Patent for Thermally-Controlled DNA Synthesis Technology

April 08, 2022

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.